Skip to content
The Chat Archive
gpt-3.5-turbo-0613· OpenAI Arena Human Preference 55K

list all the biologics indicadet for ulcerative colitis and the success rate in the…

  1. User

    list all the biologics indicadet for ulcerative colitis and the success rate in the following format: vendor, biologic name, success rate

  2. Assistant

    Vendor: AbbVie Biologic Name: Humira (adalimumab) Success Rate: Approximately 30-40% of patients achieve clinical remission after treatment with Humira.

    Vendor: Janssen Biotech Biologic Name: Remicade (infliximab) Success Rate: Around 50% of patients experience clinical response and remission with Remicade.

    Vendor: Takeda Pharmaceuticals Biologic Name: Entyvio (vedolizumab) Success Rate: Clinical remission rates with Entyvio range from 30% to 40% in patients with ulcerative colitis.

    Vendor: Pfizer Biologic Name: Xeljanz (tofacitinib) Success Rate: Studies have shown that approximately 25-30% of patients achieve remission with Xeljanz.

    Vendor: Celltrion Healthcare Biologic Name: Remsima (infliximab biosimilar) Success Rate: Similar to Remicade, Remsima has a success rate of around 50% in inducing and maintaining remission.

    Please note that success rates may vary depending on individual patient factors and the stage/severity of ulcerative colitis. It is always recommended to consult with a healthcare professional for personalized treatment options and success rates.

  3. User

    list all the biologics indicadet for ulcerative colitis and the success rate in the following format: vendor, biologic name, commercial name, success rate in a strict conscie format

  4. Assistant

    Vendor: AbbVie Biologic Name: Adalimumab Commercial Name: Humira Success Rate: 30-40%

    Vendor: Janssen Biotech Biologic Name: Infliximab Commercial Name: Remicade Success Rate: 50%

    Vendor: Takeda Pharmaceuticals Biologic Name: Vedolizumab Commercial Name: Entyvio Success Rate: 30-40%

    Vendor: Pfizer Biologic Name: Tofacitinib Commercial Name: Xeljanz Success Rate: 25-30%

    Vendor: Celltrion Healthcare Biologic Name: Infliximab biosimilar Commercial Name: Remsima Success Rate: 50%

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.